Discontinuation of Heart Failure Therapy in patients Undergoing Non-Cardiac surgery: Data from a Real-world Cohort Malik Elharram MD¹, Xiaoming Wang PhD, ² Pishoy Gouda MB BCh BAO¹Michelle M.Graham MD^1 [1] University of Alberta, Division of Cardiology and Mazankowski Alberta Heart Institute, Edmonton, Alberta, Canada [2] Research Facilitation, Alberta Health Services, Edmonton, Alberta, Canada **Disclosures:** None Funding: None Word Count: 3136 **Abstract: 295** Corresponding author: Dr. Michelle Graham, MD, FRCPC, FCCS Professor of Medicine Mazankowski Alberta Heart Institute, University of Alberta Hospital 0A8.32, 8440 112 Street Edmonton, Alberta T6G 2B7 Canada

1 Abstract 2 **Background and Aims:** Patients with heart failure (HF) with reduced ejection fraction (HFrEF) 3 are at high risk for cardiovascular events following non-cardiac surgery. The perioperative 4 period represents many challenges to maintain guideline directed medical therapy (GDMT). We 5 examined GDMT use in HFrEF patients following non-cardiac surgery, and the association of 6 medication changes with cardiovascular outcomes. 7 Methods: Using linked administrative databases, a retrospective cohort of HFrEF patients 8 9 undergoing major non-cardiac surgery between 2008 and 2020 was formed. Pre-operative use of 10 GDMT was determined by outpatient prescriptions up to 90 days prior to surgery. Changes in 11 GDMT was defined as discontinuation or a dose reduction (≥50%) of baseline therapies at 90 12 days after discharge. The primary composite outcome was HF hospitalization or all-cause 13 mortality at one-year adjusted for age, sex, components of the Revised Cardiac Risk Index and 14 the Charlson Comorbidity index. 15 16 Results: Of 397,829 index surgeries, there were 7667 (2%) patients with pre-existing HFrEF on 17 at least one GDMT (50.6% female; mean age: 75 +/- 12 years). At 90 days post-operatively, 46% 18 of patients had undergone major changes to GDMT. Compared to patients who continued 19 GDMT, patients with any change to therapy had a higher incidence of the primary outcome (52% 20 vs. 46%, aOR: 1.14, 95% CI: 1.03-1.25) and all-cause mortality at one year (8.5% vs. 4.9%, 21 aOR: 1.57, 95% CI: 1.3-1.90).

Conclusion: Among patients with HFrEF undergoing major non-cardiac surgery, few are on optimal GDMT, and perioperative changes to GDMT is associated with higher odds for HF hospitalization or death. Key Words: Heart failure, perioperative, non-cardiac surgery, guideline directed medical therapy

Introduction

1

2

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

Heart failure (HF) is highly prevalent among older adults undergoing non-cardiac surgery, and with a rising elderly population with underlying cardiovascular risk, this estimate is projected to continue to increase. HF is an established independent risk factor for adverse perioperative outcomes and is associated with a three to five-fold increase in perioperative mortality.^{2,3} Patients with HF with reduced ejection fraction (HFrEF) are a subset of patients at higher risk, and depressed left ventricular ejection fraction is an important predictor of adverse cardiovascular outcomes following surgery. 4 Guideline directed medical therapy (GDMT) including a beta blocker (BB), renin angiotensin system inhibitor (RASi), mineralocorticoid receptor antagonist (MRA), and recently a sodium glucose co-transporter 2 inhibitor (SGLT-2i), improve morbidity and mortality in HFrEF, 5-10 yet their utilization in the perioperative period remains unclear. The pathogenesis of cardiovascular events in the perioperative period results from focal surgical or anesthetic triggers that initiate inflammatory, hypercoagulable, and hypoxic states, 11 which may lead to decompensation in patients with pre-existing HFrEF. Furthermore, postoperative hypotension and renal failure may lead to challenges in reinitiating or continuing GDMT, which may worsen short and long-term HF outcomes. In prior studies of non-surgical hospitalized patients with HFrEF, discontinuation of RASi, BB or MRA at discharge was associated with an increased risk for HF readmission, and short and long-term mortality. 12-14 The perioperative period represents many challenges to maintain guideline directed medical therapy (GDMT) in HFrEF patients following major surgery. We aim to examine the contemporary use of GDMT for HFrEF following non-cardiac surgery, and the association of changes to these therapies with HF related outcomes.

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

Methods Data Source: A population-based cohort of patients who underwent non-cardiac surgery in the province of Alberta, Canada was formed, which has previously been described. ¹⁵ The dataset was created by linking 5 administrative databases in Alberta using each patients' provincial health number: (1) Alberta Inpatient Discharge Abstract Database, which includes information on all admissions to acute care facilities including admission diagnosis and inpatient surgical procedures; (2) the Pharmaceutical Information Network (PIN) database, which includes records of every individual's active and previous prescription outpatient medications in Alberta, regardless of coverage. Over the counter medications are not captured in this database; (3) the Alberta Health Care Practitioner Claims Database, which includes physician claims for outpatient services; (4) Alberta Registry data, in which deaths are recorded; and (5) the Alberta Health Services Laboratory database, which is the repository for all inpatient and outpatient laboratory investigations. **Population selection:** We identified a cohort of surgical patients with pre-existing HFrEF who were discharged alive following hospitalization for major non-cardiac surgery in Alberta. We examined patients admitted for major surgical procedures pertaining to intrathoracic, orthopaedic, intraperitoneal, vascular, and pelvic surgeries (Supplementary Table 1) If an individual underwent >1 surgical procedure during the study period, only the first surgery was used. Patients needed to have filled a prescription for either a RASi (angiotensin converting enzyme inhibitor, angiotensin receptor blocker, or angiotensin receptor-neprilysin inhibitor), BB, or MRA within 90 days (to account for stockpile medications) prior to surgery. We did not consider the use of SGLT-2i as our cohort preceded the widespread adoption of these

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

medications into HF guidelines. Surgical procedures were identified using ICD-9-CM and CCI procedural codes, as per our prior study. 15 We excluded patients undergoing cardiac or minor surgical procedures. Patients with HFrEF were defined as having at least 1 inpatient admission or at least 2 outpatient clinic visits with diagnosis of HFrEF by ICD code within 5 years of surgery (ICD-9-CM or ICD-10-CM) codes 428.2 or I50.2 (systolic HF) or 428.4 or I50.4 (combined systolic and diastolic HF). 16 **Exposure:** The exposure group was based on continuation of preoperative doses of GDMT (BB, RASi, and/or MRA) compared to changes to therapy, which were defined as either discontinuation or dose reduction of therapy. Baseline use of GDMT was defined as a medication that was dispensed within 90 days prior to admission for surgery to account for stockpiled medication. Continuation status was defined as patients having a record of an outpatient prescription filled within 90 days following discharge from non-cardiac surgery. 90days was used as our threshold as that is the longest interval that a pharmacy can dispense medications in our jurisdiction. Our secondary exposure was a dose reduction of HF therapy, defined as a \geq 50% reduction in dose from baseline, within 90 days following discharge. Data on medication use were extracted from the pharmaceutical information network (PIN) database. **Covariates:** Baseline comorbidities were obtained from the discharge abstract database using International Classification of Diseases, Tenth Revision codes (Supplementary Table 2). This included components of the Revised Cardiac Risk Index (RCRI) score ¹⁷ (1) history of ischemic heart disease; (2) heart failure; (3) stroke or transient ischemic attack; (4) insulin-treated diabetes; (5) creatinine ≥ 177 µmol/L (from most recent creatinine in the Alberta Health Services

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

Laboratory database); and (6) high-risk surgery (intrathoracic, vascular, and intraperitoneal). Preoperative BNP and post-operative creatinine were further obtained from the Alberta Health Services Laboratory database. We also included any prior history of atrial fibrillation, type 1 or type 2 diabetes mellitus, hypertension, dyslipidemia, and components of the Charlson comorbidity index.¹⁸ Outcomes: Our primary outcome was a composite of all-cause mortality or hospitalization for HF at one year. HF hospitalization was defined as an inpatient admission for HF using a hospital inpatient record using ICD-10 codes (I50, I110). Vital status was obtained from the Alberta registry. Patients were followed from the date of cohort entry (90 days after discharge from noncardiac surgery) until the occurrence of the outcome of interest or until the end of follow-up at one year. Statistical analysis: Descriptive analysis compared baseline characteristics of patients who continued GDMT without any changes, compared to patients who underwent changes (either discontinuation or dose reduction) using mean and standard deviation (SD) for continuous variables and frequency distribution for categoric variables. We stratified changes in GDMT based on their baseline use of either one, two or all three GDMT prior to non-cardiac surgery. A logistic regression model was used to examine predictors of changes in GDMT. We estimated an adjusted odds ratio with 95% CI to assess the one-year odds for readmission for HF or all-cause mortality, adjusted for: age, sex, components of RCRI risk score (history of ischemic heart disease, stroke or TIA, insulin treated diabetes, AKI (Cr > 177) and high-risk surgery) and

1 Charlson comorbidity index. SAS Enterprise Guide 8.3 (SAS Institute) was used for all statistical

analyses.

Results

Baseline characteristics

From October 1st, 2008 - September 30th, 2020, there were 552,224 surgeries performed in the province of Alberta, which included 397,829 major non-cardiac surgical procedures. Of those, we identified 7667 (1.9%) patients with a diagnosis of HFrEF who were on at least one class of GDMT prior to surgery (RASi, BB, or MRA) (**Supplementary Figure 1**). The mean age of patients were 75 years +/-12.3 years and 51.7% were female. The most common surgical procedures performed were orthopaedic in 4067 (53%) followed by intraperitoneal 2475 (32%) and pelvic 699 (9%). Following major non-cardiac surgery, 3546 patients (46%) experienced changes to baseline GDMT, which included discontinuation of at least one class of medication in 2334 (30%) or dose reduction >50% in a further 1212 (16%) patients. Individuals who had there HF therapy discontinued or dose reduced were more likely to be older, female, and have a higher prevalence of chronic kidney disease, cerebral vascular disease, atrial fibrillation/flutter, or HF hospitalization within the prior year. Pre and post operative creatinine and pre-operative BNP (where available) were higher amongst patients who underwent changes to GDMT (**Table 1**).

Guideline Directed Medical Therapy Utilization

Overall, 5724 (74%) of patients with HFrEF were on monotherapy with GDMT prior to non-cardiac surgery. For patients on monotherapy, the most common GDMT class was a RASi (87%), followed by an MRA (8%), and a beta blocker (5%). Two agents were used in 1631 (21%) of patients prior to non-cardiac surgery, with the most common combination being a

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

RASi+ MRA (54%), followed by a BB + RASi (41%). Only 312 (4%) of patients were on triple therapy (Table 2 & Supplementary Table 3). At 90 days following major non-cardiac surgery, 4131 (72.2%) of patients on one, 1019 (62.5%) on two, and 183 (58.7%) on all three GDMT classes continued their medications without changes. For patients on monotherapy, an MRA was the most frequently discontinued therapy after surgery in 150 patients (34%) of prior users. For patients on dual therapy, a BB + MRA and a RASi + MRA were more likely to have discontinued at least one medication during follow up. For patients on triple therapy at baseline, 129 (42%) of patients discontinued at least one therapy. Dose reduction of HF therapy occurred in 906 (22%) on one therapy, 264 (26%) on two therapies, and 42 (22%) of patients on three therapies. For patients on monotherapy, the most common medication to undergo a dose reduction was an MRA in 68 patients (24%). For patients on dual therapy the most common combination to undergo a dose reduction of at least one therapy was a BB+ MRA (28%) followed by a RASi+ MRA (26%) (Table 3 & Supplementary **Table 4).** Factors associated with discontinuation or dose reduction to GDMT therapy at followup included older age, prior history of atrial fibrillation/flutter, heart failure admission in the prior year, orthopaedic surgery, and elevation in preoperative BNP and post operative creatinine (Table 4). **Clinical Events** At one year follow-up, the composite of either HF hospitalization or death occurred in 3782 (49.3%) of patients. Compared to patients who continued GDMT, patients with any change to therapy had a higher incidence of the primary outcome (52% vs. 47%, aOR: 1.14, 95% CI: 1.04-1.25). Medication changes to patients on one and three therapies were associated with an

- increased odds for the primary outcome (one therapy: 52% vs. 48%, aOR: 1.13 (1.01-1.25); three
- 2 therapies: 56% vs. 36%, aOR: 1.9, 95% CI: 1.17-3.1). Medication changes to patients on two
- 3 therapies at baseline was not associated with an increased odds for the primary outcome (aOR:
- 4 1.07, 95% CI: 0.88-1.31) (**Table 5**). Overall, 504 (7%) of patients died within one year following
- 5 non-cardiac surgery. Compared to patients who continued their GDMT, patients with any change
- 6 to GDMT had significant risk of mortality (8.5% vs. 4.9%, aOR: 1.57, 95% CI: 1.30-1.90).
- 7 Mortality was significantly higher in patients who underwent changes to one therapy (aOR: 1.55,
- 8 95% CI: 1.24-1.93), but without any significant difference in patients on two and three therapies,
- 9 albeit a low number of events (Supplementary Table 5).

Discussion

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

In this large retrospective cohort of patients with HFrEF undergoing major non-cardiac surgery we observed that patients with HFrEF demonstrate a high rate of major cardiovascular events, with one in two being admitted for a heart failure exacerbation or death. Few patients with HFrEF are on optimal GDMT prior to surgery (4%) and nearly half of patients underwent significant dose reductions/discontinuation of GDMT in the peri-operative period. These changes to GDMT were associated with higher odds for HF hospitalization or mortality at one year. Together, our findings identify important real-world gaps in GDMT utilization in HFrEF patients following major surgery and emphasize the need for careful perioperative assessment and monitoring, and close outpatient follow-up to improve treatment in line with current guideline recommendations. 19-21 Pre-existing HF is among the most significant risk factors for perioperative cardiovascular complications. In an analysis of 23,340 chronic heart failure patients undergoing major non-cardiac surgery, the risk adjusted mortality within 30 days of surgery was 11.7% for patients with pre-existing HF compared to 6.6% for patients with coronary artery disease.²² Furthermore, there is a graded risk in patients with a lower left ventricular ejection fraction (EF). In a cohort of patients with chronic HF undergoing non-cardiac surgery, the 90-day postoperative mortality rate was lowest amongst patients with preserved EF (4.88%) and highest in patients with an EF of 30-39% (6.58%) and an EF of <30 % (8.34%). The elevated risk for poor outcomes extends beyond the perioperative period, with a cohort of patients with chronic HF undergoing elective or emergency surgery in Sweden demonstrating a one-year mortality of 16% for elective surgery and 39% for emergency surgery. ²⁴ Consistent with prior studies, we found that nearly half of patients with HFrEF undergoing major non-cardiac surgery were hospitalized

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

for HF or died within the year following surgery. The long-term risk of cardiovascular events following surgery was comparable to data from patients admitted with a HF exacerbation, ^{25,26} which remains one of the poorest prognostic factors in HF patients.²⁷ Admission for major surgery in patients with HFrEF may signify an important clinical event akin to a HF hospitalization that requires careful clinical assessment and diligent outpatient follow-up. While evidence from several landmark clinical trials have demonstrated the effectiveness of pharmacological therapy in improving morbidity and mortality in patients HFrEF, 5-10 we noted a low proportion of patients on adequate (triple therapy) GDMT prior to non-cardiac surgery. Our findings appear to be consistent with studies done in the real-world setting, where GDMT in patients with HFrEF has been shown to be lower than levels achieved in clinical trials. In a retrospective observational study of 17,106 patients with HFrEF with an incident HF hospitalization, 23% of patients were not on any HF therapy on admission and only 13% were on triple therapy. 13 Similarly in a large Canadian cohort of HFrEF, only 20% of patients were on triple therapy at 6 months following an index hospitalization for HF, and only 8.3% achieved optimal GDMT dose.²⁸ Utilization of GDMT within our cohort was lower than these observational studies (only 4% on triple therapy), and may be related to an older cohort with more comorbidities, and more advanced HF. Additionally, roughly one third of patients in our cohort did not have a recent HF hospitalization, which is an important triggering event for medication assessment and titration.²⁹ While current perioperative guidelines recommend adequate optimization of GDMT in HFrEF prior to elective major non-cardiac surgery, 30 our findings from a generalizable non-cardiac surgical cohort suggest underperformance in the realworld setting.

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

We also found that significant changes to GDMT occurred in HFrEF patients following non-cardiac surgery. In our cohort, nearly one-half of patients experienced discontinuation or dose-reduction of therapy at 90 days following discharge. Hemodynamic or biochemical changes in the perioperative period may provide barriers to restarting or initiating GDMT in this population. Perioperative acute kidney injury (AKI) occurs between 6.3-13.4% of patients undergoing major non-cardiac surgery, ³¹ and the presence of pre-existing HF further increases this risk.³² Additionally, multiple perioperative factors may lead to disruption of potassium homeostasis leading to hyperkalemia.³³ Renal dysfunction and hyperkalemia in the perioperative setting may lead to hesitancy to restarting a RASi or an MRA. Indeed, within our cohort, an MRA or RASi were the most frequent medications to undergo changes or discontinuation, and pre-existing chronic kidney disease and postoperative creatinine were among the strongest predictors for changes in therapy. Furthermore, hypotension from the effects of anesthetic and analgesic agents, shifts in fluid balance, or bleeding may further serve as a barrier to continuing or restarting therapy. Our analysis also identified that age, renal dysfunction, underlying atrial fibrillation, and more advanced HF (higher BNP and recent HF admission) were associated with changes to GDMT. Under-titration and discontinuation of GDMT are known to occur more frequently in elderly patients with increased medical comorbidities, ³⁴ despite the robust benefit demonstrated in this population.³⁵ This further illustrates the risk-treatment paradox in HF, where patients with the greatest need for GDMT are paradoxically the least likely to receive appropriate therapy. Discontinuation or dose reduction of GDMT in HFrEF patients following surgery was associated with adverse outcomes, including a 14% increased odds for HF hospitalization or mortality at one year. This association appeared to be strongest in the subgroup of patients who

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

were preoperatively treated with triple therapy, where HFrEF patients have been shown to achieve the most clinical benefit.³⁶ Furthermore, we found that changes in GDMT were associated with a 57% increase in all-cause mortality at one year. This is consistent with prior observational studies suggesting worsening clinical outcomes in HF patients who discontinued GDMT following admission for HF. 12-14 In a large observational study of patients admitted with decompensated HF, discontinuation of GDMT, including ACE inhibitors/ARBs, beta-blockers, and MRAs, were associated with a 30% increase in 1-year all-cause mortality compared with maintaining GDMT.³⁷ Similarly in an analysis from the Get With The Guidelines-Heart Failure Registry, discontinuation of ACEi/ARB among patients hospitalized for HFrEF was associated with a significantly higher 90-day and 1-year mortality and 30-day HF readmission compared to those who continued therapy. ¹⁴ Finally, doses of GDMT below the target recommended by clinical trials ⁵⁻¹⁰ have been associated with poorer outcomes. ³⁸ Our results extend these prior observations to a non-cardiac surgical HFrEF population, and further illustrate the harm that discontinuation or dose reduction of GDMT may have on long-term clinical outcomes. Our findings demonstrate important limitations in the contemporary management of HFrEF patients undergoing major non-cardiac surgery and emphasize the need for a coordinated and multidisciplinary approach to care and follow-up of this high-risk cohort. Following surgery, patients with HFrEF may benefit from a multidisciplinary care model between surgery, anesthesia, and cardiology/internal medicine to ensure adequate clinical assessment of hemodynamics, volume status, and biochemistry to target early re-initiation of GDMT. The perioperative setting may further serve as a key opportunity to address gaps in medical therapy including initiation, titration or switching of therapies prior to discharge. It remains imperative that HFrEF patients have early follow-up with an outpatient specialist for reassessment of

1 clinical status and consideration for early medication reinitiation/titration, to improve treatment

in keeping with guideline recommendations. 19-21

Limitations

The present results should be taken in the context of several limitations. As this was an administrative dataset, we were unable to capture echocardiographic measures of EF or functional class as markers of more advanced HF. However, the use of ICD-10 codes for patients with HFrEF, has been recently shown to accurately identify patients with reduced ejection fraction when defined as an EF <50%. ³⁹ Furthermore, we were unable to capture the rationale for discontinuation or dose reduction to therapy. Although we attempted to adjust for clinically important comorbidities in the relationship between changes in therapy and outcomes, the possibility for residual and unmeasured confounding exists. Finally given the period of study (2008-2020) our cohort predates the widespread use of SGLT-2i into HF guidelines, and we therefore did not consider the use these classes of medications in our study.

Conclusion

In conclusion, among a generalizable cohort of patients with HFrEF undergoing major non-cardiac surgery, few (4%) are on optimal GDMT pre-operatively. Furthermore roughly half of patients with HFrEF will undergo further significant reductions in their GDMT post-operatively. These deleterious perioperative changes to GDMT are associated a 14% increased risk of HF hospitalization and all-cause mortality. Our findings confirm the need for careful multidisciplinary perioperative assessment and early outpatient follow-up to improve treatment and outcomes in this high-risk population.

References:

1

9

12

16

21

25

30

34

38

43

- 2 [1] Hammill, B. G., Curtis, L. H., Bennett-Guerrero, E., O'Connor, C. M., Jollis, J. G., Schulman,
- 3 K. A., & Hernandez, A. F. (2008). Impact of heart failure on patients undergoing major
- 4 noncardiac surgery. *The Journal of the American Society of Anesthesiologists*, *108*(4), 559-567.
- 6 [2] van Diepen, S., Bakal, J. A., McAlister, F. A., & Ezekowitz, J. A. (2011). Mortality and
- 7 readmission of patients with heart failure, atrial fibrillation, or coronary artery disease
- 8 undergoing noncardiac surgery: an analysis of 38 047 patients. Circulation, 124(3), 289-296.
- 10 [3] Patel, A. Y., Eagle, K. A., & Vaishnava, P. (2015). Cardiac risk of noncardiac
- surgery. *Journal of the American College of Cardiology*, 66(19), 2140-2148.
- 13 [4] Huang, Y. Y. C., Chen, L., & Wright, J. D. (2022). Comparison of Perioperative Outcomes in
- 14 Heart Failure Patients With Reduced Versus Preserved Ejection Fraction After Noncardiac
- 15 Surgery. *Annals of Surgery*, *275*(4), 807-815.
- 17 [5] Pfeffer, M. A., McMurray, J. J., Velazquez, E. J., Rouleau, J. L., Køber, L., Maggioni, A. P.,
- 18 ... & Califf, R. M. (2003). Valsartan, captopril, or both in myocardial infarction complicated by
- 19 heart failure, left ventricular dysfunction, or both. New England Journal of Medicine, 349(20),
- 20 1893-1906.
- 22 [6] McMurray, J. J., Packer, M., Desai, A. S., Gong, J., Lefkowitz, M. P., Rizkala, A. R., ... &
- 23 Zile, M. R. (2014). Angiotensin–neprilysin inhibition versus enalapril in heart failure. N Engl J
- 24 *Med*, 371, 993-1004.
- 26 [7] Packer, M., Fowler, M. B., Roecker, E. B., Coats, A. J., Katus, H. A., Krum, H., ... &
- DeMets, D. L. (2002). Effect of carvedilol on the morbidity of patients with severe chronic heart
- 28 failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS)
- 29 study. Circulation, 106(17), 2194-2199.
- 31 [8] Pitt, B., Zannad, F., Remme, W. J., Cody, R., Castaigne, A., Perez, A., ... & Wittes, J. (1999).
- 32 The effect of spironolactone on morbidity and mortality in patients with severe heart failure. *New*
- 33 *England Journal of Medicine*, *341*(10), 709-717.
- 35 [9] McMurray, J. J., Solomon, S. D., Inzucchi, S. E., Køber, L., Kosiborod, M. N., Martinez, F.
- A., ... & Langkilde, A. M. (2019). Dapagliflozin in patients with heart failure and reduced
- ejection fraction. New England Journal of Medicine, 381(21), 1995-2008.
- 39 [10] Cole, G. D., Patel, S. J., Zaman, N., Barron, A. J., Raphael, C. E., Mayet, J., & Francis, D.
- 40 P. (2014). "Triple therapy" of heart failure with angiotensin-converting enzyme inhibitor, beta-
- blocker, and aldosterone antagonist may triple survival time: shouldn't we tell patients?. *JACC*:
- 42 *Heart Failure*, 2(5), 545-548.
- 44 [11] Smilowitz, N. R., & Berger, J. S. (2016). Perioperative management to reduce cardiovascular
- 45 events. *Circulation*, *133*(11), 1125-1130.

- 1 [12] Gilstrap, L. G., Fonarow, G. C., Desai, A. S., Liang, L., Matsouaka, R., DeVore, A. D., ... &
- 2 Bhatt, D. L. (2017). Initiation, continuation, or withdrawal of angiotensin-converting enzyme
- 3 inhibitors/angiotensin receptor blockers and outcomes in patients hospitalized with heart failure
- 4 with reduced ejection fraction. *Journal of the American Heart Association*, 6(2), e004675.
- 6 [13] Wirtz, H. S., Sheer, R., Honarpour, N., Casebeer, A. W., Simmons, J. D., Kurtz, C. E., ... &
- 7 Globe, G. (2020). Real-world analysis of guideline-based therapy after hospitalization for heart
- 8 failure. Journal of the American Heart Association, 9(16), e015042.
- 10 [14] Bhagat, A. A., Greene, S. J., Vaduganathan, M., Fonarow, G. C., & Butler, J. (2019).
- 11 Initiation, continuation, switching, and withdrawal of heart failure medical therapies during
- 12 hospitalization. *JACC: Heart Failure*, 7(1), 1-12.
- 14 [15] Gouda, P., Wang, X., McGillion, M., & Graham, M. M. (2021). Underutilization of
- perioperative screening for cardiovascular events after noncardiac surgery in Alberta. Canadian
- 16 *Journal of Cardiology*, *37*(1), 57-65.

9

13

17

21

25

28

33

38

- 18 [16] Butler, J., Djatche, L. M., Sawhney, B., Chakladar, S., Yang, L., Brady, J. E., & Yang, M.
- 19 (2020). Clinical and economic burden of chronic heart failure and reduced ejection fraction
- following a worsening heart failure event. Advances in therapy, 37(9), 4015-4032.
- 22 [17] Ford, M. K., Beattie, W. S., & Wijeysundera, D. N. (2010). Systematic review: prediction of
- perioperative cardiac complications and mortality by the revised cardiac risk index. Annals of
- 24 *internal medicine*, 152(1), 26-35.
- 26 [18] Charlson, M., Szatrowski, T. P., Peterson, J., & Gold, J. (1994). Validation of a combined
- 27 comorbidity index. Journal of clinical epidemiology, 47(11), 1245-1251.
- 29 [19] McDonald, M., Virani, S., Chan, M., Ducharme, A., Ezekowitz, J. A., Giannetti, N., ... &
- 30 Yip, A. M. C. (2021). CCS/CHFS heart failure guidelines update: defining a new pharmacologic
- 31 standard of care for heart failure with reduced ejection fraction. Canadian Journal of
- 32 *Cardiology*, 37(4), 531-546.
- 34 [20] Heidenreich, P. A., Bozkurt, B., Aguilar, D., Allen, L. A., Byun, J. J., Colvin, M. M., ... &
- 35 Yancy, C. W. (2022). 2022 AHA/ACC/HFSA guideline for the management of heart failure: a
- 36 report of the American College of Cardiology/American Heart Association Joint Committee on
- 37 Clinical Practice Guidelines. *Journal of the American College of Cardiology*, 79(17), e263-e421.
- 39 [21] McDonagh, T. A., Metra, M., Adamo, M., Gardner, R. S., Baumbach, A., Böhm, M., ... &
- 40 Kathrine Skibelund, A. (2021). 2021 ESC Guidelines for the diagnosis and treatment of acute
- 41 and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute
- 42 and chronic heart failure of the European Society of Cardiology (ESC) With the special
- 43 contribution of the Heart Failure Association (HFA) of the ESC. European heart journal, 42(36),
- 44 3599-3726.

- 1 [22] Hernandez, A. F., Whellan, D. J., Stroud, S., Sun, J. L., O'Connor, C. M., & Jollis, J. G.
- 2 (2004). Outcomes in heart failure patients after major noncardiac surgery. Journal of the
- 3 American College of Cardiology, 44(7), 1446-1453.
- 5 [23] Lerman, B. J., Popat, R. A., Assimes, T. L., Heidenreich, P. A., & Wren, S. M. (2019).
- Association of left ventricular ejection fraction and symptoms with mortality after elective noncardiac surgery among patients with heart failure. *Jama*, 321(6), 572-579.
- 9 [24] Faxén, U. L., Hallqvist, L., Benson, L., Schrage, B., Lund, L. H., & Bell, M. (2020). Heart
- 10 failure in patients undergoing elective and emergency noncardiac surgery: Still a poorly
- addressed risk factor. *Journal of Cardiac Failure*, 26(12), 1034-1042.
- 13 [25] Parizo, J. T., Kohsaka, S., Sandhu, A. T., Patel, J., & Heidenreich, P. A. (2020). Trends in
- readmission and mortality rates following heart failure hospitalization in the Veterans Affairs
- 15 Health Care System from 2007 to 2017. *JAMA cardiology*, 5(9), 1042-1047.
- 17 [26] Gupta, A., Allen, L. A., Bhatt, D. L., Cox, M., DeVore, A. D., Heidenreich, P. A., ... &
- 18 Fonarow, G. C. (2018). Association of the hospital readmissions reduction program
- implementation with readmission and mortality outcomes in heart failure. JAMA
- 20 *cardiology*, *3*(1), 44-53.

8

12

16

21

25

29

33

40

- 22 [27] Ho, K. K., Anderson, K. M., Kannel, W. B., Grossman, W., & Levy, D. (1993). Survival
- after the onset of congestive heart failure in Framingham Heart Study
- 24 subjects. *Circulation*, 88(1), 107-115.
- 26 [28] Wahid, M., Aghanya, V., Sepehrvand, N., Dover, D. C., Kaul, P., & Ezekowitz, J. (2022).
- 27 Use of Guideline-Directed Medical Therapy in Patients Aged≥ 65 Years After the Diagnosis of
- Heart Failure: A Canadian Population-Based Study. *CJC open*, 4(12), 1015-1023.
- 30 [29] Srivastava, P. K., DeVore, A. D., Hellkamp, A. S., Thomas, L., Albert, N. M., Butler, J., ...
- 31 & Fonarow, G. C. (2021). Heart failure hospitalization and guideline-directed prescribing
- patterns among heart failure with reduced ejection fraction patients. *Heart Failure*, 9(1), 28-38.
- 34 [30] Halvorsen, S., Mehilli, J., Cassese, S., Hall, T. S., Abdelhamid, M., Barbato, E., ... & Touyz,
- R. M. (2022). 2022 ESC Guidelines on cardiovascular assessment and management of patients
- 36 undergoing non-cardiac surgery: Developed by the task force for cardiovascular assessment and
- 37 management of patients undergoing non-cardiac surgery of the European Society of Cardiology
- 38 (ESC) Endorsed by the European Society of Anaesthesiology and Intensive Care
- 39 (ESAIC). European heart journal, 43(39), 3826-3924.
- 41 [31] Shaw, A. D., Khanna, A. K., Smischney, N. J., Shenoy, A. V., Boero, I. J., Bershad, M., ...
- & Stapelfeldt, W. H. (2022). Intraoperative hypotension is associated with persistent acute
- 43 kidney disease after noncardiac surgery: a multicentre cohort study. British Journal of
- 44 Anaesthesia.

- 1 [32] Thakar, C. V., Arrigain, S., Worley, S., Yared, J. P., & Paganini, E. P. (2005). A clinical score to predict acute renal failure after cardiac surgery. *Journal of the American Society of*
- 3 Nephrology, 16(1), 162-168.
- 5 [33] Ayach, T., Nappo, R. W., Paugh-Miller, J. L., & Ross, E. A. (2015). Postoperative
- 6 hyperkalemia. *European Journal of Internal Medicine*, 26(2), 106-111.
- 8 [34] Fiuzat, M., Ezekowitz, J., Alemayehu, W., Westerhout, C. M., Sbolli, M., Cani, D., ... &
- 9 O'Connor, C. M. (2020). Assessment of limitations to optimization of guideline-directed medical
- therapy in heart failure from the GUIDE-IT trial: a secondary analysis of a randomized clinical
- 11 trial. JAMA cardiology, 5(7), 757-764.
- 13 [35] Seo, W. W., Park, J. J., Park, H. A., Cho, H. J., Lee, H. Y., Kim, K. H., ... & Choi, D. J.
- 14 (2020). Guideline-directed medical therapy in elderly patients with heart failure with reduced
- ejection fraction: a cohort study. BMJ open, 10(2), e030514.
- 17 [36] Burnett, H., Earley, A., Voors, A. A., Senni, M., McMurray, J. J., Deschaseaux, C., & Cope,
- 18 S. (2017). Thirty years of evidence on the efficacy of drug treatments for chronic heart failure
- with reduced ejection fraction: a network meta-analysis. Circulation: Heart Failure, 10(1),
- 20 e003529.

12

16

21

26

30

36 37

38

39

40

- 22 [37] Tran, R. H., Aldemerdash, A., Chang, P., Sueta, C. A., Kaufman, B., Asafu-adjei, J., ... &
- Rodgers, J. E. (2018). Guideline-directed medical therapy and survival following hospitalization
- 24 in patients with heart failure. Pharmacotherapy: The Journal of Human Pharmacology and Drug
- 25 Therapy, 38(4), 406-416.
- 27 [38] Januzzi, J. L., Ahmad, T., Mulder, H., Coles, A., Anstrom, K. J., Adams, K. F., ... &
- O'Connor, C. M. (2019). Natriuretic peptide response and outcomes in chronic heart failure with
- reduced ejection fraction. *Journal of the American College of Cardiology*, 74(9), 1205-1217.
- 31 [39] Bates, B. A., Akhabue, E., Nahass, M. M., Mukherjee, A., Hiltner, E., Rock, J., ... &
- 32 Setoguchi, S. (2023). Validity of international classification of diseases (ICD)-10 Diagnosis
- 33 codes for identification of acute heart failure hospitalization and heart failure with reduced
- versus preserved ejection fraction in a national medicare sample. Circulation: Cardiovascular
- 35 *Quality and Outcomes*, 16(2), e009078.

Table 1. Baseline Clinical Characteristics

Past Medical History	p-value
Sex (% Female) 7667 3963 (51.69%) 4121 (51.69%) 1926 (46.74%) 3546 (50.14%) Past Medical History Hypertension (%) 7667 5772 (75.28%) 4121 (3092 (75.03%)) 3546 (2680 (75.58%)) Dyslipidemia (%) 7667 1991 (25.97%) 4121 (26.23) 3546 (910 (25.66%)) Insulin dependent Type 2 Diabetes Mellitus (%) 1090 (14.22%) 4121 (27.35%) 3546 (27.21%) Non insulin dependent Type 2 Diabetes Mellitus (%) (27.21%) 4121 (27.35%) 3546 (27.04%) Mellitus (%) 4121 (27.35%) 3546 (27.21%) 959 (27.04%) Peripheral vascular disease (%) (43.99%) 4121 (27.35%) 3546 (27.21%) Peripheral vascular disease (%) (13.76%) 4121 (27.35%) 3546 (27.21%) Cerebral vascular disease (%) (13.76%) 4121 (27.35%) 3546 (27.21%) Chronic Kidney 7667 (27.21%) 4121 (27.35%) 3546 (27.21%) Ohronic Kidney 7667 (27.21%) 4121 (27.35%) 3546 (27.21%) Ohronic Kidney 7667 (27.21%) 4121 (27.35%) 3546 (27.21%) Ohronic Kidn	<.0001
Past Medical History	
Hypertension (%) 7667 5772 (75.28%) 3546 2680 (75.58%) Dyslipidemia (%) 7667 1991 (25.97%) Insulin dependent Type 2 Diabetes Mellitus (%) (14,22%) Non insulin dependent 7667 2086 (27.21%) Beripheral vascular disease (%) (13.76%) Cerebral vascular disease (%) (11.16%) Cerebral vascular disease (%) (11.16%) Chronic Kidney Disease (%) (16.72%) History of HF admission within the past year (%) Charlson comorbidity index (mean, SD) (7667 1.89 (1.19)) RCRI score (mean, SD) (7667 1.89 (1.19)) Testem (1.19) (121 1.85 (1.20) 3546 2680 (75.58%)) 3546 2680 (75.58%) 3546 2680 (75.58%) 3546 910 (25.66%) 3546 508 (14.33%) 3546 508 (14.33%) 3546 959 (27.04%) 959 (27.04%) 1127 (27.35%) 3546 1579 (44.53%) 3546 496 (13.99%) 3546 496 (13.99%) 3546 496 (13.99%) 3546 424 (11.96%) 4121 (33 (15.36%) 3546 424 (11.96%) 3546 49 (18.30%) 3546 49 (18.30%) 3546 49 (18.30%) 3546 4121 (363 (15.36%) 3546 424 (11.96%) 3546 4121 (364 (84.89%)) 3546 424 (11.96%) 3546 4121 (364 (84.89%)) 3546 424 (11.96%) 3546 4121 (363 (15.36%)) 3546 424 (11.96%) 3546 4121 (363 (15.36%)) 3546 424 (11.96%) 3546 4121 (363 (15.36%)) 3546 424 (11.96%) 3546 4121 (363 (15.36%)) 3546 424 (11.96%) 3546 4121 (363 (15.36%)) 3546 424 (11.96%) 3546 4121 (363 (15.36%)) 3546 424 (11.96%) 3546 4121 (363 (15.36%)) 3546 424 (11.96%) 3546 4121 (363 (15.36%)) 3546 424 (11.96%) 3546 4121 (363 (15.36%)) 3546 424 (11.96%) 3546 4121 (363 (15.36%)) 3546 424 (11.96%) 3546 4121 (363 (15.36%)) 3546 424 (11.96%) 3546 4121 (363 (15.36%)) 3546 424 (11.96%) 3546 4121 (363 (15.36%)) 3546 424 (11.96%) 3546 4121 (363 (15.36%)) 3546 424 (11.96%) 3546 4121 (363 (15.36%)) 3546 424 (11.96%) 3546 4121 (363 (15.36%)) 3546 424 (11.96%) 3546 4121 (363 (15.36%)) 3546 424 (11.96%) 3546 424 (11.96%) 3546 424 (11.96%) 3546 424 (11.96%) 3546 424 (11.96%) 3546 424 (11.96%) 3546 424 (11.96%) 3546 424 (11.96%) 3546 424 (11.96%) 3546 424 (11.96%) 3546 424 (11.96%) 3546 424 (11.96%) 3546 424 (11.96%) 3546 424 (11.96%) 3546 424 (11.96%) 3546 424 (11.96%)	0.0029
Composition	
Insulin dependent Type 7667 1090 4121 582 (14.12%) 3546 508 (14.33%) Non insulin dependent Type 2 Diabetes Mellitus (%) (14,22%) (27.21%) (27	0.5793
2 Diabetes Mellitus (%) Non insulin dependent Type 2 Diabetes Mellitus (%) Ischemic heart disease (%) Peripheral vascular disease (%) Cerebral vascular disease (%) Chronic Kidney Chronic Kidney Chronic Kidney Disease (%) Chronic Kidney Chronic Kidne	0.5712
Type 2 Diabetes Mellitus (%) Ischemic heart disease (%) Peripheral vascular disease (%) Cerebral vascular disease (%) Chronic Kidney Disease (%) Atrial fibrillation/flutter (%) History of HF admission within the past year (%) Charlson comorbidity index (mean, SD) RCRI score (mean, SD) RCRI score (mean, SD) RCRI score (mean, SD)	0.7995
(%) (43.99%) 559 (13.56%) 3546 496 (13.99%) Peripheral vascular disease (%) 7667 1055 (13.76%) 4121 (10.48%) 3546 496 (13.99%) Cerebral vascular disease (%) 7667 856 (11.16%) 4121 (10.48%) 3546 (424 (11.96%)) Chronic Kidney Disease (%) 7667 (1282 (16.72%)) 4121 (16.72%) 633 (15.36%) 3546 (49 (18.30%)) Atrial fibrillation/flutter (%) 3166 (41.29%) 4121 (1567 (38.02%)) 3546 (1599 (45.09%)) History of HF admission within the past year (%) 7667 (5225 (4121 (26.144))) 2674 (64.89%) 3546 (2551 (71.94%)) Charlson comorbidity index (mean, SD) 7667 (1.20) 1.39 (1.20) 4121 (1.26 (1.14)) 3546 (1.54 (1.25)) RCRI score (mean, SD) 7667 (1.89 (1.19)) 4121 (1.85 (1.20)) 3546 (1.94 (1.18))	0.7662
disease (%) (13.76%) 4121 432 (10.48%) 3546 424 (11.96%) Cerebral vascular disease (%) 7667 856 (11.16%) 4121 (33 (15.36%)) 3546 (49 (18.30%)) Chronic Kidney Disease (%) 7667 (16.72%) 1282 (10.48%) 3546 (49 (18.30%)) Atrial fibrillation/flutter (%) 7667 (3166 (41.29%)) 4121 (1567 (38.02%)) 3546 (1599 (45.09%)) History of HF admission within the past year (%) 7667 (5225 (4121 (2674 (64.89%))) 2674 (64.89%)) 3546 (2551 (71.94%)) Charlson comorbidity index (mean, SD) 7667 (1.20) 1.39 (1.20) 4121 (1.26 (1.14)) 3546 (1.54 (1.25)) RCRI score (mean, SD) 7667 (1.89 (1.19)) 4121 (1.85 (1.20)) 3546 (1.94 (1.18))	0.3811
Cerebral vascular disease (%) 7667 856 (11.16%) 4121 432 (10.48%) 3546 424 (11.96%) Chronic Kidney Disease (%) 7667 1282 (16.72%) 4121 (633 (15.36%)) 3546 649 (18.30%) Atrial fibrillation/flutter (%) 7667 3166 (41.29%) 4121 (1567 (38.02%)) 3546 (1599 (45.09%)) History of HF admission within the past year (%) 7667 5225 (68.15%) 4121 (2674 (64.89%)) 3546 (2551 (71.94%)) Charlson comorbidity index (mean, SD) 7667 1.39 (1.20) 4121 (1.26 (1.14)) 3546 (1.54 (1.25)) RCRI score (mean, SD) 7667 1.89 (1.19) 4121 (1.85 (1.20)) 3546 (1.94 (1.18))	0.5920
Chronic Kidney Disease (%) 7667 1282 (16.72%) 4121 (16.72%) 633 (15.36%) 3546 (49 (18.30%)) Atrial fibrillation/flutter (%) 7667 3166 (41.29%) 4121 (1567 (38.02%)) 3546 (1599 (45.09%)) History of HF admission within the past year (%) 7667 5225 (68.15%) 4121 (2674 (64.89%)) 3546 (2551 (71.94%)) Charlson comorbidity index (mean, SD) 7667 1.39 (1.20) 4121 (1.26 (1.14)) 3546 (1.54 (1.25)) RCRI score (mean, SD) 7667 1.89 (1.19) 4121 (1.85 (1.20)) 3546 (1.94 (1.18))	0.0410
Atrial fibrillation/flutter (%) 7667 3166 (41.29%) 4121 1567 (38.02%) 3546 1599 (45.09%) History of HF admission within the past year (%) 7667 5225 (68.15%) 4121 2674 (64.89%) 3546 2551 (71.94%) Charlson comorbidity index (mean, SD) 7667 1.39 (1.20) 4121 1.26 (1.14) 3546 1.54 (1.25) RCRI score (mean, SD) 7667 1.89 (1.19) 4121 1.85 (1.20) 3546 1.94 (1.18)	0.0006
History of HF admission within the past year (%) 7667 5225 (68.15%) 4121 (68.15%) 2674 (64.89%) 3546 (2551 (71.94%) Charlson comorbidity index (mean, SD) 7667 1.39 (1.20) 4121 (1.26 (1.14)) 3546 (1.54 (1.25)) RCRI score (mean, SD) 7667 1.89 (1.19) 4121 (1.85 (1.20)) 3546 (1.94 (1.18))	<.0001
Charlson comorbidity index (mean, SD) 7667 1.39 (1.20) 4121 (1.26 (1.14)) 3546 (1.54 (1.25)) RCRI score (mean, SD) 7667 1.89 (1.19) 4121 (1.85 (1.20)) 3546 (1.94 (1.18))	<.0001
RCRI score (mean, SD) 7667 1.89 4121 1.85 (1.20) 3546 1.94 (1.18)	<.0001
	0.0016
Surgery type	
Vascular (%) 7667 316 4121 183 (4.44%) 3546 133 (3.75%)	0.1297
Intraperitoneal (%) 7667 2475 4121 1410 (34.21%) 3546 1065 (30.03%)	<.0001
Intrathoracic (%) 7667 110 4121 71 (1.72%) 3546 39 (1.10%)	0.0222
Pelvic (%) 7667 699 4121 438 (10.63%) 3546 261 (7.36%)	<.0001
Orthopedic (%) 7667 4067 4121 2019 (48.99%) 3546 2048 (57.76%)	<.0001
Laboratory investigations	
Pre-operative 5264 99 (78 – 2763 97 (77 – 130) 2501 101 (78 – 140) umol/L)	0.0017
Pre-operative BNP (median, ng/ml) 676 403 299 357 (174 – 670) 377 434 (198 - 878 – 781.5)	0.0178
Pre-operative NT- proBNP (median, ng/ml) 540 1908 (652 - 4531.5) 1640.5 (568.5 - 256 2102 (728 - 47) 4037)	752.5) 0.0763
Post-operative creatinine (median, 130)	0.0054

umol/L)				

Legend: SD: standard deviation, IQR: Interquartile range, HF: Heart failure, BNP: Brain natriuretic peptide,

Table 2 – Discontinuation of Guideline Directed Medical Therapy Following Major Non-

5 Cardiac Surgery

	Pre-operative use	90-days following non-cardiac surgery				
	of GDMT (n= 7667)	Continued all therapies (N= 5333)	Discontinuation of 1 class (N= 1991)	Discontinuation of 2 classes (N= 304)	Discontinuation of 3 classes (N= 39)	
On one therapy	5724 (74.66%)	4131 (72.17%)	1593 (27.83%)			
On two therapies	1631 (21.27%)	1019 (62.48%)	333 (20.42%)	279 (17.11%)		
On three therapies	312 (4.07%)	183 (58.65%)	65 (20.83%)	25 (8.01%)	39 (12.50%)	

Legend: GDMT: Guideline directed medical therapy; One therapy: Either beta blocker (BB) or renin angiotensin system inhibitor (RASi), or mineralocorticoid receptor blocker (MRA); On two therapies: combination of RASI+MRA, BB+ RASi, or MRA+BB; On three therapies: BB+MRA+RASi

Table 3 – Dose Reduction of Guideline Directed Medical Therapy Following Major Non-

14 Cardiac Surgery

	Pre-operative use of GDMT	90-days following non-cardiac surgery				
(n= 7667)	Continued all therapies (N=5333)	Continued without dose reduction (N=4121)	Dose reduction of 1 class (N=1090)	Dose reduction of 2 classes (N=116)	dose reduction of 3 classes (N=6)	
On one therapy	5724 (74.66%)	4131 (72.17%)	3225 (78.07%)	906 (21.93%)		
On two therapies	1631 (21.27%)	1019 (62.48%)	755 (74.09%)	157 (15.41%)	107 (10.50%)	
On three therapies	312 (4.07%)	183 (58.65%)	141 (77.05%)	27 (14.75%)	9 (4.92%)	6 (3.28%)

Legend: GDMT: Guideline directed medical therapy, One therapy: Either BB, RASi, or MRA, On Two therapies:
 Combination of RASI+ MRA, BB+ RASi, or MRA+BB. On three therapies: BB+MRA+RASi

Table 4. Factors associated with discontinuation or dose reduction in therapy following non-cardiac surgery

Factors	Discontinuation or dose reduction in therapy (OR with 95% CI)	p value
Age from 66 to 75 vs Age \leq 65	1.209 (1.054 - 1.387)	0.0142
Age from 76 to 85 vs Age \leq 65	1.424 (1.249 - 1.624)	0.0859
$Age > 85 \text{ vs } Age \le 65$	1.848 (1.594 - 2.143)	<.0001
Hypertension (Yes vs No)	0.912 (0.817 - 1.017)	0.0970
Atrial fibrillation/flutter (Yes vs No)	1.209 (1.098 - 1.331)	0.0001
History of HF admission within the past year (Yes vs No)	1.268 (1.143 - 1.407)	<.0001
Orthopedic (Yes vs No)	1.356 (1.233 - 1.491)	<.0001
Pre-Operative creatinine >177 μmol/L (Yes vs No)	1.230 (0.976 - 1.549)	0.0791
BNP level 1 vs level 0	1.351 (0.885 - 2.060)	0.6625
BNP level 2 vs level 0	1.507 (1.265 - 1.795)	0.0595
NT-proBNP level 1 vs level 0	1.668 (1.000 - 2.783)	0.1255
NT-proBNP level 2 vs level 0	1.236 (1.015 - 1.505)	0.7883
Post-Operative creatinine >177 μmol/L (Yes vs No)	1.266 (1.009 - 1.590)	0.0417

Legend: HF: heart failure, BNP: Brain natriuretic peptide

Table 5 – Discontinuation or Dose Reduction in Therapy on HF Hospitalization or All-cause

Mortality at 1-year

1 2

	Heart Failure Hospitalization or All-Cause Mortality					
	No discontinuation or dose reduction in therapy	Discontinuation or dose reduction in therapy				
	Events n = (%)	Events n = (%)	Unadjusted OR (95% CI)	Adjusted OR* (95% CI)		
On HF therapy at baseline (one, two or three therapies)	1947 (47.25%) among 4121	1835 (51.75%) among 3546	1.197 (1.094, 1.310)	1.140 (1.039, 1.251)		
One therapy	1533 (47.53%) among 3225	1292 (51.70%) among 2499	1.181 (1.064, 1.312)	1.126 (1.010, 1.254)		
Two therapies	363 (48.08%) among 755	448 (51.14%) among 876	1.130 (0.930, 1.373)	1.073 (0.879, 1.311)		
Three therapies	51 (36.17%) among 141	95 (55.56%) among 171	2.206 (1.396, 3.484)	1.900 (1.176, 3.069)		

Legend: GDMT: Guideline directed medical therapy, HF: Heart failure, OR: Odds ratio, CI: Confidence Interval

4 Legen 5 *Adju 6 index. 7

^{*}Adjusted odds ratio: age, sex, components of revised cardiac risk index risk score and Charlson comorbidity